or
forgot password

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies


Phase 2
N/A
N/A
Open (Enrolling)
Both
Acute Myelogenous Leukemia, Lymphoid Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia, Myeloproliferative Disorder, Anemia, Aplastic, Myelodysplastic Syndromes

Thank you

Trial Information

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies


Inclusion Criteria:



- Zubrod performance status 2 (See Appendix B).

- Life expectancy is not severely limited by concomitant illness.

- Adequate cardiac and pulmonary function. Patients with decreased LVEF or PFTS will be
evaluated by cardiology or pulmonary prior to enrollment on this protocol.

- Serum creatinine <1.5 mg/dL or Creatinine Clearance >50 ml/min .

- Serum bilirubin 2.0 mg/dl, SGPT <3 x upper limit of normal

- No evidence of chronic active hepatitis or cirrhosis.

- HIV-negative

- Patient is not pregnant

- Patient or guardian able to sign informed consent.

Exclusion Criteria:

- N/A

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Disease-free survival

Outcome Time Frame:

annually

Safety Issue:

No

Principal Investigator

Andrew Artz, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Chicago

Authority:

United States: Institutional Review Board

Study ID:

11300A

NCT ID:

NCT00683046

Start Date:

November 2001

Completion Date:

November 2013

Related Keywords:

  • Acute Myelogenous Leukemia
  • Lymphoid Leukemia
  • Chronic Myelogenous Leukemia
  • Malignant Lymphoma
  • Hodgkin's Disease
  • Chronic Lymphocytic Leukemia
  • Myeloproliferative Disorder
  • Anemia, Aplastic
  • Myelodysplastic Syndromes
  • Relapsed or refractory acute myelogenous or lymphoid leukemia.
  • Acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence.Chronic myelogenous leukemia in accelerated phase or blast-crisis.
  • Chronic myelogenous leukemia in chronic phase
  • Chronic myelogenous leukemia in accelerated phase or blast-crisis
  • Recurrent or refractory malignant lymphoma or Hodgkin's disease.
  • Chronic lymphocytic leukemia, relapsed or with poor prognostic features.
  • Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.
  • Severe aplastic anemia after failure of immunosuppressive therapy.
  • Myelodysplastic syndromes (including PNH)
  • Multiple myeloma at high risk for disease recurrence.
  • Anemia
  • Anemia, Aplastic
  • Hodgkin Disease
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Lymphoma
  • Myelodysplastic Syndromes
  • Preleukemia
  • Myeloproliferative Disorders
  • Hematologic Neoplasms

Name

Location
The University of Chicago Chicago, Illinois  60637